Summary The effect of 45min systemic heating at 41°C on plasma and RIF-1 tumour pharmacokinetics of intraperitoneally administered melphalan (MEL) was studied in C3H mice. This heat dose causes greater potentiation of MEL in tumour than in marrow cells, resulting in a therapeutic gain for the combined therapy (Honess & Bleehen, 1985) . MEL (7.5mgkg-1) was administered at the start of heating and concentrations assayed from 20-90min by high-performance liquid chromatography (HPLC). With or without heat peak concentrations were achieved by 20 min and were 3 to 4 pg ml -1 in plasma and 1-3 g g-1 in tumour. Higher MEL concentrations in both plasma and tumour were found in heated animals at times after 20 min from injection, but the effect was greater in plasma (2.5-4 fold) than in tumour (1.5-2 fold) where differences were not always significant. At 40 min after a dose of 7.5 mg kg 1, plasma and tumour concentrations in heated animals were equivalent to those after 12.5mgkg-1 and 8.5mgkg-1, respectively, without heating. Tumour/plasma ratios were usually lower in heated than in unheated animals where they often exceeded 100%. The apparent plasma elimination half-life (ti) was 17.5-25min in unheated and 24 44 min in heated animals. The area under the curve (AUC) was increased by a factor of 1.2-1.5 in heated animals, at least partly due to a decrease in volume of distribution. The heat induced increase in MEL exposure may be involved in the enhanced response to the drug, but does not appear to explain the therapeutic gain compaired to MEL alone.
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We have previously shown that potentiation of melphalan (MEL) by 45min whole body heating at 41°C is greater in two tumours than in normal marrow stem cells (CFUs) in C3H mice (Honess & Bleehen, 1985) . This results in a therapeutic gain for the combination of whole body heat with MEL. In contrast, under the same conditions, no gain was found for the combination with 3 other alkylating agents, (chlorambucil, cisplatinum and cyclophosphamide), or the nitrosoureas BCNU and CCNU (Honess & Bleehen, 1982 , 1985 . One of the possible mechanisms may be alteration of drug pharmacokinetics by heat, a topic on which few studies have been carried out (Mimnaugh et al., 1978; Honess et al., 1980; Magin et al., 1980) . We have therefore studied the effect of systemic heat at 41°C on the pharmacokinetrics of MEL in plasma and in the RIF-1 tumour in order to investigate whether any heat induced changes in pharmacokinetics would account for the greater heat potentiation in tumour. We have used a paired-ion reversed-phase high-performance liquid chromatography (HPLC) technique to assay MEL in plasma and tumour in unheated and heated mice. 
Materials and methods

Mice
Female C3H/He mice were obtained from Olac (Southern) Ltd, Bicester, UK. Female C3H/Km mice were bred in this unit. Mice were treated at 20-30 g weight.
Tumour
The RIF-1 tumour described by Twentyman et al. (1980) was grown i.m. in the left hind leg, initiated by an inoculum of 105 cells from culture. Animals were treated when tumours reached mean leg diameters of 9-11 mm, usually on Day 12 or 13 after inoculation. These tumours were slightly larger than those used in the work in which heat potentiation of mel was demonstrated (8-9.5mm diameter, Honess & Bleehen, 1985) . This was in order to provide sufficient tumour for MEL assay. All experiments reported in this paper were carried out on tumour-bearing animals.
Hyperthermia
The method of inducing systemic hyperthermia by enclosing animals in an incubator has been previously described (Honess and Bleehen 1982 (Honess & Bleehen, 1985 Analysis of the significance of differences between MEL concentrations in heated and unheated animals was carried out using the Wilcoxon Mann-Whitney test. Differences in elimination half-lives were compared using students t distribution.
Results
Preliminary experiments with 7.5 mg kg1 MEL given intraperitoneally at the start of heating showed a broad peak of MEL concentration from 10-20 min after injection, which was unchanged by heat. However at times after 20 min higher concentrations were seen in both plasma and tumour of heated animals. In 4 subsequent experiments, with larger numbers of anumals per group (4 and 5), MEL concentrations were measured only at 20, 40, 60 and 90 min after drug administration. At later times the concentrations of drug fell very close to or below the limit of detection (-0.01Ig ml -1).
Results for 2 experiments with i.p. administered MEL are shown in Figure 1 and they illustrate the greatest and smallest effects of heat observed in this series of 4 experiments. Peak plasma concentrations of 3-4 jug ml-1 were found at 20 min, and no difference was seen in heated animals. In Experiment A plasma concentrations ( Figure 1 therefore indicate that systemic heat at 41°C causes higher plasma and tumour MEL concentrations than are found in unheated animals, but the effect is greater in plasma than in tumour.
Tumour/plasma ratios for both experiments shown in Figure 1 are presented in Table I . The main feature of these data, confirmed in other experiments, is that tumour/plasma ratios are lower in heated animals. With the exception of the 60min for Experiment B, tumour/plasma ratios measured from 40 to 90 min were 1.5 to 2 times higher in unheated mice. Tumour/plasma ratios greater than 100% were found in Experiment A and in other experiments (not shown).
It seemed possible that the effects shown in Figure 1 might be due to the effect of heat on MEL uptake from the peritoneum. We therefore repeated the experiment giving MEL i.v. (Experiment C) and the results for plasma are shown in Figure 2 . Plasma MEL concentrations were again higher in heated than in unheated animals by a factor of 1.5-2, and the results, show the same trend as those shown in Figure 1 . This indicates that the increased MEL concentrations in heated animals cannot be attributed to the effect of heat on uptake from the peritoneum. Figure 1 (panels a and estimation of residual alkylating activity using the Epstein reagent or by titration of acid release respectively (Workman et al., 1976) . A widely used index of drug exposure is the area under the concentration x time curve (AUC). AUCs have been calculated for plasma and tumour in unheated and heated animals for experiments A, B and C and are presented in Table IV . The change in plasma AUC in heated animals is similar to the change in tumour AUC, an increase by a factor of 1.2 to 1.5. The changes in AUC brought about by heat depend on the precise shapes of the control and heat curves in each particular case. In Experiment A the increase in plasma AUC was slightly greater than in tumour whereas in Experiment B this small difference was reversed. We conclude that in terms of AUC, heat causes no consistent elevation in tumour compared to plasma MEL exposure.
We wished to obtain some estimate of the MEL dose in unheated animals which would give MEL concentrations similar to those measured in heated animals after 7.5mgkg-1 i.p. MEL (i.e. an isoeffect dose), and thus to derive some alternative measure of drug exposure modification by heat. On the basis of Experiment A and another (not shown) the 40min time point was selected as that when the difference between plasma concentrations in heated and unheated animals was greatest, and so in experiments B and C we also measured MEL concentrations for a range of drug doses in unheated animals at 40min. The data are shown in Figure 3 . Lines of best fit have been drawn through the data by eye for unheated animals, and hence the iso-effect dose was estimated. For plasma in Experiment B (i.p. administration, panel a) the value is 12.5mgkg-1 and in Experiment C (i.v. administration, panel c) the value is 13.0mgkg-1. (Alberts et al., 1980) and nitrogen mustard in rabbits (Shingleton, 1962) . Reduced concentrations in mouse tumours have been reported for misonidazole (Honess et al., 1980) and cyclophosphamide and thiotepa (Longo et al., 1983) , also under conditions of drug potentiation. Osieka et al. (1978) found no difference in methyl-CCNU uptake in human colon xenografts in nude mice.
In this study we have shown that systemic heat at 41PC for 45 min causes an increase in both plasma and tumour concentrations of MEL, but there is no evidence for a greater elevation in tumour compared to plasma.
In general, tumour/plasma ratios were higher in unheated animals than in heated ones. Nonetheless, the time course of the rise and fall of tumour/plasma ratios, peaking 40-60 min after drug administration, was similar in both heated and unheated animals. Tumour/plasma ratios greater than 100% were found in both heated and unheated tumours; however, the highest values were found in unheated tumours, as were a larger proportion of high values. The accumulation of MEL in murine leukaemia and human breast tumour cells at normal temperature in vitro occurs by means of two distinct amino acid carriers (Vistica, 1979 , Begleiter et al., 1979 Nonetheless, Begleiter et al. (1980) quote cell:medium ratios of about 3.5 in MCF-7 breast cancer cells in the presence of 10,pM 14C melphalan, which is -3 pg ml -1. We found tumour/plasma ratios of up to 1.7 following peak plasma concentrations of about 3 pg ml-1 (Figure 1 , (Furner et al., 1976) . It has been shown that MEL does not undergo important metabolism (Evans et al., 1982) but that a major route of elimination of MEL in all species examined is biliary excretion, (Furner & Brown, 1980 The data for intravenously administered MEL (Figure 2) , also showing an increase in plasma MEL concentration, indicated that the effect of heat was not primarily on MEL uptake from the peritoneum. The higher peak MEL concentration in heated animals and unchanged t' were compatible with a probable reduction of apparent volume of distribution of the MEL in heated mice. This would be consistent with the weight loss observed during heating.
It is interesting that in two experiments (one i.p., one i.v.) heating produced mean MEL concentrations 40 min after administration of 7.5mg kg-1 equivalent to those produced by 1.7 x that dose in unheated animals ( Figure 3 ). For bone marrow stem cells, 12.5mg kg-1 MEL in unheated animals in equitoxic with 7.3mg kg-1 in heated animals (Honess & Bleehen, 1985) , also a ratio of 1.7. If toxicity of MEL to bone marrow stem cells is closely related to MEL plasma concentration, as would seem possible, then the effect of heat on MEL plasma concentration would be sufficient to account for the heat potentiation of MEL toxicity in CFUs. However, in RIF-I tumour 12.5mgkg-t MEL in unheated animals is equitoxic with only 4.6mg kg-1 MEL in heated animals (Honess & Bleehen, 1985) , a ratio of 2.7. This ratio is substantially larger than the ratio of doses resulting in equal MEL plasma concentrations at 40min in unheated and heated animals (1.7, Figure  3 , panel a). It is also very much greater than the ratio of doses resulting in equal tumour concentrations at 40 min in unheated and heated animals, which is 1.1 (Figure 3, panel b) . Although the small increase in MEL concentration in heated tumours presumably contributes to the MEL potentiation, it would appear to be only a small component of the mechanism.
While it seems reasonable to compare changes in tumour pharmacokinetics with changes in drug toxicity in the tumour under the same conditions, it is less satisfactory to compare changes in plasma pharmacokinetics with changes in drug toxicity to the marrow. Although the marrow is well perfused, MEL access to cells requires carrier mediation, and the behaviour of such carriers in CFUs, especially under heated conditions, cannot be easily predicted. It would therefore be preferable to monitor MEL pharmacokinetics in the CFUs. However since the CFUs comprise only 0.015% of the nucleated cells of the bone marrow, and are only functionally identificable, this is clearly impossible. Nonetheless there is a good correlation between increase in plasma MEL concentration and toxicity to CFUs.
The broad conclusion from this study is that systemic heat at 41°C does increase plasma and tumour MEL concentrations. However while changes in plasma pharmacokinetics may account for the increase in MEL toxicity to marrow, the changes in tumour pharmacokinetics can only contritute in a minor way to the greater heat potentiation of MEL in tumour. These results therefore do not explain the therapeutic gain found for this combination of heat and MEL, and the reason for this probably lies at the cellular biochemical level.
